Seeking Alpha

A SMARTER GREEK

A SMARTER GREEK
Send Message
View as an RSS Feed
View A SMARTER GREEK's Comments BY TICKER:
Latest  |  Highest rated
  • "Not cheap" Pharmacyclics is headed higher on Ibrutinib potential: JPMorgan [View news story]
    tremendous move! Great product saving and prolonging life, with much less if any bad side effects!
    Bob Duggan the CEO/Chrmn has done this before. ISRG at 12 up to
    500+ now at 350.
    Same guy, great visionary that gets things done! Always first with new technology that works and changes the field.
    Sep 26 12:24 PM | 2 Likes Like |Link to Comment
  • Pharmacyclics (PCYC) submits an NDA for ibrutinib (developed with JNJ's Janssen) for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. The drug has Breakthrough Therapy designation for both indications and is a major catalyst for the shares. This is one to watch closely given the takeout chatter around ONXX. In other company news, Jesse McGreivy is promoted to Chief Medical Officer. [View news story]

    Great news ahead of schedule! Remember CEO/Chrm of this baby was also very insturmental with launching ISRG and got involved at $12.00! now over $450 and billions in sales.

    He is smart and cares a lot about helping others!
    Jul 10 08:09 AM | Likes Like |Link to Comment
  • Pharmacyclics (PCYC) submits an NDA for ibrutinib (developed with JNJ's Janssen) for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. The drug has Breakthrough Therapy designation for both indications and is a major catalyst for the shares. This is one to watch closely given the takeout chatter around ONXX. In other company news, Jesse McGreivy is promoted to Chief Medical Officer. [View news story]
    Ahead of schedule! Nice....remember CEO/Chrmn of this company is same person that launched the technology responsible for and thus ISRG for 12 to 450+. His involvement was at $12.00
    He is a smart dude and good guy who cares a lot for others!
    Jul 10 08:07 AM | Likes Like |Link to Comment
  • Pharmacyclics (PCYC +9.5%) trades higher today after RBC Capital ups the shares to Outperform and raises its price target to $100 from $70. The firm cites optimism over a number of upcoming catalysts for its leukemia drug Ibrutnib, which is being jointly developed by PCYC and JNJ's Janssen Pharmaceuticals. [View news story]
    Mr. Duggan the CEO and Chairman..is repeating again with a phenominlal product(s), and successfull company in PCYC as he did
    with ISRG..from 12 to 500!
    Real company, great products, good management..de ja vu!
    May 13 01:17 PM | 1 Like Like |Link to Comment
  • Pharmacyclics (PCYC +1.7%) gets a bump higher this morning after announcing its Phase III clinical trial using Ibrutinib versus Chlorambucil to treat chronic lymphocytic leukemia and small lymphocyctic lymphoma has enrolled its fifth patient. The enrollment subsequently triggers a fourth $50M milestone payment obligation from JNJ's Janssen Biotech, who is collaborating with PCYC on Ibrutinib in oncology. On Monday, the drug was granted a 3rd "Breakthrough Therapy Designation" by the FDA. [View news story]
    Mr. Duggan the COB and CEO is doing it again witth PCYC! He did it with ISRG from 12 to over $500.00 and changed the robotic surgery industry and he is doing it again in the Oncology industry. We need more guys like him.
    Apr 11 10:38 AM | Likes Like |Link to Comment
  • After The Bloodbath, Where Does Pharmacyclics Go From Here? [View article]
    You have a very determined and focused COB/CEO with PCYC. His goal is to bring to market a product(s) that really make a difference and help mankind.
    As he did with ISRG. when he became a part of it basically very little sales, now billions in sales, $10-$12.00, cklosed today at $524.

    I like to bet on a winner.
    Nov 15 04:28 PM | Likes Like |Link to Comment
  • After The Bloodbath, Where Does Pharmacyclics Go From Here? [View article]
    to Mr. Li and others ( I alreadys sent this but didn't print?)
    Thanks for clarification. The insiders emplowees/directors etc own over 20 % correct but Mr. Duggan the COB owns about 80-90% of that. He shas stated he is not selling. ( By the way he is the same person that gace birth and is still on the Board of the Da Vinci robotics machine..ISRG!) If you examine the stock options the have an average vested perios of 3-5 years. So if they do need to sell because of the change in the tax laws comint, maybe 100,00+ shares if tha, nothing! Also the Leukimia Phas 2 and 3 testinghas been ophenominal and I wouldn't be surprised if another payment shortl! As fot eh MM tsing it was very preliminary and only with 14 out of 420 patients! They has some good resuklts anyway so they are just increases the dosage. Not threat to J & J continued investment at all anothe 725 mil to go!!!
    A
    Nov 15 11:06 AM | Likes Like |Link to Comment
  • Why Immunogen Is Undervalued [View article]
    RE: PCYC also to Mr. Li,
    Thanks for some clarification on the 19% drop in PCYC. What should be known and further clarified is that the employees/officers etc stock which is held, nearly 80-90% of that is owned by the COB Mr. Bob Duggan and he is Not selling per his statementt. Also if you go back and research most stock options they are all vested options take average 3-5 years+ to vest. So I figure max if some need to sell before year end because this tax laws changing is maybe 100,000 shares+ if that!..nothing! Also about the MM testing only 14 people were tested and there were some good results anyway,, however not up to their standards, but still had good effects, so they are simply increasing the dosage and with a much bigger group 400+ testing. The leukemia testing in phase 2 and 3 has been phenomenal! Hope this helps clear it all up further.
    Andy Golden Greek
    Nov 15 10:50 AM | Likes Like |Link to Comment
  • Pharmacyclics' (PCYC) Phase II trial of its ibrutinib drug in patients with mantle cell lymphoma, a rare type of non-Hodgkin's lymphoma, enrolls its 5th patient, thereby triggering a second milestone payment of $50M from J&J (JNJ) unit Janssen Biotech. Additional $50M payments could be triggered up to a total of $250M. (First payment[View news story]
    Been waiting for PCYC to sell of a little to get a little more. That hasn't worked! The train gas left the station!
    Guess options best way!
    Aug 20 09:02 AM | Likes Like |Link to Comment
  • Pharmacyclics' (PCYC) Phase II trial of its ibrutinib drug in patients with mantle cell lymphoma, a rare type of non-Hodgkin's lymphoma, enrolls its 5th patient, thereby triggering a second milestone payment of $50M from J&J (JNJ) unit Janssen Biotech. Additional $50M payments could be triggered up to a total of $250M. (First payment[View news story]
    Been waiting for it to sell off at least a little, so I can get a little more! Still waiting!

    I guess options the brstw ay right now.

    The Greek
    Aug 20 09:01 AM | Likes Like |Link to Comment
  • Pharmacyclics (PCYC +3.8%) trades higher after the FDA designates Orphan Drug Status for its chronic lymphocyctic leukemia treatment. [View news story]
    For those that might not know. The COB/CEO Bob Duggan is also the the same guy responsoble and still on the Board of ISRG and the Da Vinci robotic surgery baby. $12.00 to over $530! Huge growth and sales.
    Apr 11 12:08 PM | Likes Like |Link to Comment
  • Pharmacyclics (PCYC) tacks on a 6.6%% gain after landing a recommendation from industry-watcher John McCamant - who calls the firm one of the most exciting names in biotech. He highlights the company's B-cell lymphoma drug that is in phase 2 and landed a deal with a unit of Johnson & Johnson that includes a $150M upfront payment and a 50/50 profit/loss split worldwide. [View news story]
    great bekliever in Mr. Duggan
    Mar 1 01:43 PM | Likes Like |Link to Comment
  • Pharmacyclics (PCYC) tacks on a 6.6%% gain after landing a recommendation from industry-watcher John McCamant - who calls the firm one of the most exciting names in biotech. He highlights the company's B-cell lymphoma drug that is in phase 2 and landed a deal with a unit of Johnson & Johnson that includes a $150M upfront payment and a 50/50 profit/loss split worldwide. [View news story]
    An important side note on PCYC: The COB and CEO Mr. Bob Duggan is same guy that is resposible for the birth of ISRG and it Da Vinci technology, with his prior Company ComputermMotion. Bottom line from just a couple$$ to over $500 a share, 2 billion in sales. Good manager, smart and good guy to follow!
    .
    Mar 1 01:42 PM | Likes Like |Link to Comment
  • Selling Short America and the Rest of the World [View article]
    IAGREE, THE MEDIA HAS PROVEN TO BE A MERCHANT OF FURTHER CHAOS/ MORE INTERESTED IN RATINGS AND GETTING A RISE IN VIEWERSHIP/ PERHAPS THE SHORTS SHOULD SELL THEIR PARENT COMPANIES SO THEY THE MEDIA TO CAN HELP THEMSELVES OUT OF A JOB.
    FIRST SIMPLE STEP JUST REINSTITUTE THE UP TICK SHORT SELL RULE, AND INCREASE ETHICS AND POLICY IN THAT SECTOR.
    A LOT MORE CAN BE DONE, BUT SIMPLY BY REVERSING THE DUMB CANCELLATION OF THE UPTICK RULE BY THE SEC, THAT WOULD HELP BIG TIME.
    IT WAS WRITTEN TO HELP PREVENT A SIMILAR SITIATION IN THE CRASHES OF THE 30'S.
    SO WHY WAS IT REVERSED..???

    ANDY
    Sep 14 11:14 AM | Likes Like |Link to Comment
  • Sell These Three Stocks Before Everyone Else Does [View article]
    ISRG/ You are trying to shake the tree.....with a maybe sell "if".
    First of all get your facts straight. 70% of sales last quarter was from the razor blades..not the razor! Less than 10 are in Europe. Those earning cash from about 650 Davinci's in USA. They can eslilly 10X Europe in the next 18 months and doublde USA. That should 3x-4X earnings from here. Plus new products and new FD approvals for other procedures. The insurance companies love this company as the averae patient stay in hopsital is cut down less than half, and much less human error. Trading wise this baby is a yo-yo, not for the weak in heart. But furure in my book shows this baby based on Actuall $$ made! This stock will be at a new high Mid-Jan. Break up to over $425 after earnings announced on Jan 31. Then with 3 to 1 split should be trading between a low of $175 to $225 this time next year! Have fun!!
    Dec 19 11:15 AM | Likes Like |Link to Comment
COMMENTS STATS
15 Comments
3 Likes